Description:

Southwest Oncology Group Registration Form (S0600) NCT00499369 Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=15404476-282E-46CA-E044-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=15404476-282E-46CA-E044-0003BA3F9857

Keywords:
Versions (5) ▾
  1. 12/18/14
  2. 1/9/15
  3. 1/9/15
  4. 6/27/15
  5. 9/20/21
Uploaded on:

September 20, 2021

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Southwest Oncology Group Registration Form (S0600) NCT00499369

No Instruction available.

  1. StudyEvent: Southwest Oncology Group Registration Form (S0600)
    1. No Instruction available.
Header
Patient demographics
Patient Gender
Patient's Ethnicity
Miscellaneous Patient Information
Method of Payment
Performance status (Stratification Factors:)
Discontinuation of oxaliplatin while on first line therapy
Planned concurrent chemotherapy
Time from last dose of bevacizumab

Similar models